NCT00562965 (Clinical Trial / Inotuzumab ozogamycin / CMC-544)

Study Title
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator’s Choice In Follicular Non-Hodgkin’s Lymphoma (NHL) (NCT00562965)

Trial Description
This protocol is designed to assess the efficacy and safety of inotuzumab ozogamicin (also known as CMC-544) given with rituximab compared to a defined investigator’s choice therapy. Subjects will be randomized to one of these two arms of the study.

This trial is sponsored by UCB Pharma/ Pfitzer. [1]

Study Data

Study Schematic 


Click here to Return to Drug map

Last Editorial review: July 31, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.